Jacobs Levy Equity Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jacobs Levy Equity Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,000	Closed	-$511K	–	1142
2021 Q2	$511K	Sell	2,000 -3,558	-64%	-$888K	﹤0.01%	856
2021 Q1	$1.48M	Sell	5,558 -1,230	-18%	-$388K	0.01%	652
2020 Q4	$2.5M	Sell	6,788 -2,902	-30%	-$832K	0.02%	524
2020 Q3	$2.37M	Buy	9,690 +3,586	+59%	+$1.12M	0.02%	492
2020 Q2	$1.76M	Buy	6,104 +3,305	+118%	+$974K	0.02%	553
2020 Q1	$571K	Buy	2,799 +2,087	+293%	+$665K	0.01%	732
2019 Q4	$318K	Sell	712 -10	-1%	-$3.55K	﹤0.01%	845
2019 Q3	$222K	Buy	+722	New	+$235K	﹤0.01%	825
2016 Q2	–	Sell	-498	Closed	-$251K	–	1246
2016 Q1	$251K	Buy	+498	New	+$248K	0.01%	919

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Jacobs Levy Equity Management's EIGR Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2021, closing a stake of 2,000 shares — an estimated $511K sold.

Jacobs Levy Equity Management first reported a position in EIGR in Q1 2016 and held it in 9 quarters. The position peaked at $2.5M in Q4 2020. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2021.

Jacobs Levy Equity Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 2,000 Eiger BioPharmaceuticals, Inc. shares in Q3 2021, an estimated $511K.
Jacobs Levy Equity Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2016 and held it in 9 quarters.
Jacobs Levy Equity Management's Eiger BioPharmaceuticals, Inc. position peaked at $2.5M in Q4 2020.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.